OBJECTIVE	Our aim was to investigate the safety , tolerability and pharmacokinetics of a new formulation and dose regimen ( intravenous bolus plus infusion ) of MCI-186 suitable for the treatment of acute ischemic stroke in Europe because the Japanese treatment protocol includes twice-a-day intravenous infusion of MCI-186 for a maximum of 14 days .\